Form 4: Larimar Therapeutics Director Acquires 19,000 Stock Options
SEC Form 4
Jeffrey W. Sherman, a director of Larimar Therapeutics, acquired 19,000 stock options on May 29, 2024, according to a recent SEC filing.
Summary
- On May 29, 2024, Jeffrey W. Sherman, a director at Larimar Therapeutics, acquired 19,000 stock options.
- The exercise price of these options is $7.07.
- The options vest on the earlier of May 29, 2025, or the date of the company's next annual meeting of stockholders, contingent upon continued service on the Board of Directors.
- The options expire on May 29, 2034.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a standard disclosure of stock option acquisition by a director. It doesn't inherently indicate positive or negative sentiment, but rather provides information for investors to interpret.
Positives
- A director's acquisition of stock options can be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company insiders.
Stakeholder Impact
- Shareholders may view this as a positive sign if they believe the director's acquisition reflects confidence in the company's future prospects.
Key Dates
| Date | Description |
|---|---|
| 05/29/2024 | Date of transaction: Director acquired 19,000 stock options. |
| 05/29/2025 | Earliest vesting date for the stock options, contingent on continued service. |
| 05/29/2034 | Expiration date of the stock options. |
| 05/31/2024 | Date of signature on the SEC filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.